Mondrian Investment Partners LTD Takes Position in Waters Corporation $WAT

Mondrian Investment Partners LTD purchased a new position in shares of Waters Corporation (NYSE:WAT) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 4,660 shares of the medical instruments supplier’s stock, valued at approximately $1,397,000.

Other hedge funds have also added to or reduced their stakes in the company. Deroy & Devereaux Private Investment Counsel Inc. grew its holdings in shares of Waters by 41.9% during the 3rd quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 13,802 shares of the medical instruments supplier’s stock valued at $4,138,000 after purchasing an additional 4,077 shares during the last quarter. Veritas Asset Management LLP acquired a new stake in Waters in the third quarter valued at approximately $175,320,000. Envestnet Asset Management Inc. boosted its position in Waters by 5.0% in the second quarter. Envestnet Asset Management Inc. now owns 126,070 shares of the medical instruments supplier’s stock valued at $44,004,000 after buying an additional 5,980 shares in the last quarter. Figure 8 Investment Strategies LLC grew its stake in shares of Waters by 46.4% during the third quarter. Figure 8 Investment Strategies LLC now owns 7,793 shares of the medical instruments supplier’s stock worth $2,336,000 after buying an additional 2,471 shares during the last quarter. Finally, Union Bancaire Privee UBP SA acquired a new position in shares of Waters during the third quarter worth $1,624,000. 94.01% of the stock is owned by institutional investors.

Waters Price Performance

Waters stock opened at $323.91 on Tuesday. The stock’s 50 day moving average is $379.34 and its 200 day moving average is $348.42. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.41 and a quick ratio of 1.01. The firm has a market cap of $19.29 billion, a P/E ratio of 30.07, a P/E/G ratio of 2.23 and a beta of 1.18. Waters Corporation has a one year low of $275.05 and a one year high of $414.15.

Waters (NYSE:WAT) last released its earnings results on Monday, February 9th. The medical instruments supplier reported $4.53 earnings per share for the quarter, beating analysts’ consensus estimates of $4.50 by $0.03. Waters had a net margin of 20.30% and a return on equity of 34.79%. The business had revenue of $932.36 million during the quarter, compared to the consensus estimate of $928.17 million. During the same quarter in the prior year, the firm posted $4.10 EPS. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. As a group, research analysts expect that Waters Corporation will post 12.86 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on WAT shares. Wells Fargo & Company dropped their price target on Waters from $415.00 to $355.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 11th. UBS Group lowered their target price on Waters from $395.00 to $370.00 and set a “neutral” rating for the company in a report on Tuesday, February 10th. Weiss Ratings reissued a “hold (c)” rating on shares of Waters in a research note on Wednesday, January 21st. Wall Street Zen cut Waters from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. Finally, William Blair assumed coverage on Waters in a research note on Monday, January 5th. They issued an “outperform” rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Waters has an average rating of “Moderate Buy” and an average target price of $397.68.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.